Online,

Online,

Online,

US,

ZIP: 00000

Phone: +14157353289

In the context of intense scrutiny over the safety and durability of blood disease-targeted gene therapies and a flurry of excitement around novel gene editing technologies, the 3rd Gene Therapy for Blood Disorders Summit will unite the leading large pharma and innovative biotechs to share essential learnings from across this rapidly evolving field, enabling you to progress your pipeline to address the significant unmet need in this field.

Focused specifically on hemophilia, beta-thallasemia and sickle cell-directed gene therapies and gene editing approaches, this event is an invaluable opportunity to learn the realities of durability challenges, understand strategies to guarantee safety at every stage of development and get a head-start in understanding the most promising technologies set to revolutionise the field.

Incorporating insights from translational, clinical and commercial industry experts, as well as leading clinicians actively involved in late-stage trials, this is your opportunity to investigate the realities of managing immunogenicity for systemically administered gene therapies, establishing less cytotoxic conditioning regimens for ex vivo approaches and prepare for the commercial reality of launching a gene therapy and ensuring there is widespread patient adoption.

URLs:
Tickets: https://go.evvnt.com/947702-2?pid=1052
Brochure: https://go.evvnt.com/947702-3?pid=1052

Prices:
Conference Only - Industry Rate - Digital Attendance: USD 2099.0,
Conference + 1 Workshop - Industry Rate - Digital Attendance: USD 2548.0,
Conference + 2 Workshops - Industry Rate - Digital Attendance: USD 2997.0,
Conference Only - Academic Rate - Digital Attendance: USD 1899.0,
Conference + 1 Workshop - Academic Rate - Digital Attendance: USD 2248.0,
Conference + 2 Workshops - Academic Rate - Digital Attendance: USD 2597.0

Gabriella Denning, VP Research and Development, Expression Therapeutics, Guy Young, Director Hemostasis and Thrombosis Center, Children's Hospital LA, Ian Winburn, Global Medical Lead Haemophilia, Pfizer, Wendy Pang, VP Research and Translational Medicine, Jasper Tx, Brian OMahoney, CEO, Irish Haemophilia Society, Clark Paramore, Head of Value Demonstration and HEOR, bluebird bio, Dawn Henke, Director, Standards Coordinating Body, Mark Trusheim, Strategic Director, NEWDIGS MIT, Adam Wufsus, Medical Director Rare Blood Disorders, Novo Nordisk, Antti Kourula, Global Vice President Commercial President, CSL Behring, Jonathan Schwarts, Chief Medical Officer, Rocket Pharmaceuticals, Lesha Shah, Co-Chair, Pediatric Gene Therapy and Medical Ethics Working Group, Glenn Mones, Advocacy Leader, The Coalition Haemophilia B, Karen Pinachyan, Head of Medical Affairs Europe, CSL Behring, Meagan O'Brien, Senior Medical Director, Regeneron, Oscar Segurado, Chief Medical Officer, ASC Therapeutics, David Wilcox, VP Research and Translational Medicine, Medical College of Wisconsin, Graham Foster, Professor of Hepatology, Queen Mary University of London, Rahul Palchaudhuri, Director of Biotherapeutics, Magenta Therapeutics